Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference

Nov 24, 2009, 13:00 ET from Accumetrics, Inc.

SAN DIEGO, Nov. 24 /PRNewswire/ -- Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy-to-use diagnostic system for measuring an individual's response to multiple antiplatelet agents (e.g. Plavix® and aspirin), announced today that Timothy I. Still, President and CEO of Accumetrics, and Gregory J. Tibbitts, Chief Financial Officer of Accumetrics, will be presenting a corporate overview at the 21st Annual Piper Jaffray Health Care Conference being held in New York City on December 1-2, 2009 at The Palace Hotel.

This presentation comes on the heels of Accumetrics' VerifyNow P2Y12 Test being one of multiple methods recently evaluated during a Late Breaking Clinical Trials session at the American Heart Association Scientific Sessions 2009.

Accumetrics' presentation will be on Tuesday, December 1, 2009 at 9:10 am eastern time. Management will also be available for one-on-one meetings with investors participating in Piper Jaffray's Health Care Conference. For those who would like to schedule an appointment with Accumetrics' management, please contact Anne Marie Fields, Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at afields@lhai.com or contact your Piper Jaffray representative.

About Accumetrics

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy to use platform to help physicians determine an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient(TM)) and clopidogrel (Plavix)), and GP IIb/IIIa inhibitors (e.g. ReoPro® and Integrilin®), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions. For more information about the Company and its products, visit www.accumetrics.com.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis. Effient is a trademark of Eli Lilly and Company.


CONTACT:
Megan Rusnack
Lippert/Heilshorn & Associates
212-838-3777
mrusnack@lhai.com

Timothy I. Still
President and CEO
Accumetrics
858-404-8260
press@accumetrics.com

SOURCE Accumetrics, Inc.



RELATED LINKS

http://www.accumetrics.com